Verified
I used Spiriva as my morning routine. By week 3 I noticed fewer pauses when climbing stairs. Dry mouth was annoying at first, then it settled after I kept water nearby and chewed sugar-free gum.
20 May 2025
Quality products
Fast & Discrete Delivery
Money-back guarantee
Spiriva
4 (4 customer reviews)Spiriva is a long-acting bronchodilator inhaler containing tiotropium, an anticholinergic medicine. It is for people with COPD, including chronic bronchitis and emphysema, who need daily symptom control. It blocks muscarinic receptors to relax airway smooth muscle and improve airflow.
Description
Spiriva is a long-acting bronchodilator containing tiotropium, primarily used to manage symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by relaxing the airways, making breathing easier for individuals experiencing bronchospasm and dyspnea.
Composition
Spiriva contains tiotropium bromide (tiotropium), an anticholinergic agent and long-acting bronchodilator.
Dosage and usage
- Route: Inhalation (capsules for inhalation; use with the HandiHaler-type device)
- Dose: 18 micrograms (0.018 mg) tiotropium per capsule
- Frequency: Inhale the contents of 1 capsule once daily (1 time/day)
- Timing: Take at the same time each day; with or without food
- How to take: Place 1 capsule into the inhaler chamber, pierce as directed by the device, and inhale the powder through the mouthpiece until the capsule is empty; repeat inhalation from the same capsule if instructed by your clinician
- Duration: Long-term maintenance treatment; continue daily as prescribed
How it works
- Route: Inhalation (capsules for inhalation)
- Dose: 18 micrograms (0.018 mg) tiotropium per capsule
- Frequency: Inhale the contents of 1 capsule once daily
- Timing: Same time each day; with or without food
- Duration: Long-term maintenance use as prescribed
- Mechanism (what this dose does): Tiotropium is a long-acting muscarinic receptor antagonist that reduces acetylcholine-mediated bronchial smooth-muscle constriction, leading to bronchodilation and improved airflow over 24 hours
Indications
Spiriva is used for long-term, once-daily maintenance treatment of bronchospasms and dyspnoea linked to chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Comparison
Spiriva is a long-acting muscarinic antagonist (LAMA) focused on bronchodilation. Other COPD controllers may focus on bronchodilation plus inflammation control.
| Option | What it contains | Best fit in COPD care |
|---|---|---|
| Spiriva | LAMA (tiotropium) | Daily maintenance bronchodilation, dyspnoea control |
| LABA/ICS inhaler | Long-acting beta-agonist + inhaled corticosteroid | When inflammation control is also needed, based on phenotype and exacerbation pattern |
| SABA or short-acting anticholinergic (e.g., ipratropium) | Short-acting bronchodilator | Rescue relief or short-term symptom spikes, not a standalone maintenance plan |
Two practical differences patients feel: LAMA therapy like Spiriva is often “quiet” (steady breathing, fewer sudden tight-chest moments), while steroid-containing inhalers can reduce inflammatory triggers but may bring hoarseness or oral thrush risk in some users. Device choice and inhalation technique can matter as much as the molecule.
Contraindications
- Hypersensitivity to tiotropium
- Hypersensitivity to atropine and its derivatives
- History of allergic reaction such as hives or facial swelling after similar anticholinergic inhalers
When this is not for you
Do not use Spiriva if you are allergic to tiotropium, or if you have reacted to atropine-like medicines or similar anticholinergic inhalers (for example with hives or facial swelling).
Use extra caution and speak with your clinician if you have kidney problems, narrow-angle glaucoma symptoms (eye pain/halos), or trouble passing urine, because Spiriva can worsen these issues.
Side effects
Most side effects of Spiriva reflect its anticholinergic action. Common ones include dry mouth, constipation, and blurred vision. Some people also report abdominal discomfort.
Side effects that deserve faster medical assessment include new or worsening chest pain, a noticeable change in heartbeat, or significant vision disturbances. Urinary retention can occur, usually as hesitancy or difficulty starting urination, and it tends to matter most in people with prostate enlargement or bladder outflow issues.
If blurred vision happens, one practical concern is accidental eye exposure from hand-to-eye contact after handling the device. Wash hands after dosing if you are prone to rubbing your eyes. [3]
Common mistakes
Using Spiriva well is mostly about avoiding a few repeat mistakes I see in real use.
- Swallowing the capsule instead of inhaling it. This reduces lung delivery and increases side effects risk in the gut.
- Exhaling into the mouthpiece before inhaling. Moisture can clump powder and reduce the delivered dose.
- Pressing the piercing button multiple times. This can shred the capsule and make inhalation feel harsh.
- Stopping Spiriva on “good breathing” days and restarting only when breathlessness returns. Maintenance therapy works best when it is steady.
- Mixing up roles: trying to use Spiriva for acute bronchospasm, then feeling it “didn’t work.”
A short, practical warning: mouth dryness is manageable.
What doctors say
In clinical practice, prescribers often reach for Spiriva when breathlessness is persistent and the goal is fewer COPD “bad days,” not just short bursts of relief. The once-daily routine helps adherence, and patients who can’t tolerate a steroid component in some combination inhalers may do well with a LAMA-focused bronchodilator plan.
Doctors also watch for a predictable early pattern: mild dry mouth in the first week or two, then improvement once hydration and oral care habits adjust. If palpitations or chest discomfort appear soon after starting, clinicians usually reassess inhaler technique, caffeine intake, and the full respiratory regimen before deciding on changes.
One nuance pulmonologists mention: when symptoms are mainly nighttime or tied to inflammation-heavy asthma, a bronchodilator-only approach may be incomplete, and therapy is often tailored with other controller classes. This is why “best inhaler” is never one-size-fits-all.
Frequently asked questions
Can Spiriva be used for sudden breathing problems or acute bronchospasm?
Spiriva is used for maintenance control, not as a rescue for acute bronchospasm. In sudden bronchospasms, patients are usually managed with a separate rapid-relief inhaler plan, while Spiriva continues as the daily controller. This distinction is consistent with how COPD maintenance bronchodilators are positioned in respiratory guidance referenced by the WHO in 2026. [5]
How long does it take for Spiriva to start working?
Many people feel some bronchodilator effect on the first day, but the bigger benefit is usually noticed after steady daily use as the airways remain more consistently open. For COPD, clinicians often assess response across the first few weeks, because flare-up frequency and exertional dyspnoea patterns take time to judge. In 2026, EMA materials describing tiotropium still frame it as a once-daily maintenance bronchodilator rather than an “instant fix.”
What if I miss a dose of Spiriva?
If you miss a dose, the typical approach is to take the next scheduled dose at the usual time and avoid doubling up. Taking two doses close together increases anticholinergic side effects such as dry mouth, palpitations, constipation, and urinary retention. This conservative approach matches standard safety messaging used in regulator-reviewed product information, including EMA-aligned guidance used in many markets.
Is Spiriva a steroid?
Spiriva is not a corticosteroid. It is an anticholinergic bronchodilator (a LAMA) and works by blocking muscarinic receptors to reduce airway smooth muscle constriction. Steroid inhalers target inflammation, while Spiriva targets bronchial tone; clinicians may combine classes when a patient’s COPD or asthma pattern calls for it, which is consistent with treatment pathways referenced by WHO respiratory guidance updates used in 2026.
Can Spiriva be used in asthma as well as COPD?
Spiriva is widely used in COPD, and in selected asthma regimens it may be added when symptoms persist despite other controller therapy. In practice, the decision depends on asthma severity, exacerbation history, and what else is already in the regimen. Treatment escalation pathways referenced by EMA-reviewed materials and global guidance sets place tiotropium as an add-on option in defined cases rather than a first-line asthma controller.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Comparison
Atrovent
20mcg
Singulair
10mg
4mg
5mg
Spiriva Current
18mcg
Symbicort
Active ingredient: Budesonide
164.5mcg
Ventolin
2mg
4mg
Spiriva: Reviews and Experiences
Verified
Breathing felt smoother in the afternoons, which used to be my worst time. I did get constipation in the first two weeks and had to adjust fibre and fluids. After that, it was fine.
7 Jun 2025
Verified
Technique mattered more than I expected. The first days I tasted the powder and thought it wasn’t going in. After my doctor rechecked how I inhaled, it worked better. I still needed my rescue inhaler during a cold.
5 Jun 2025
Verified
It helped the tightness but I got blurry vision once when I rubbed my eye after dosing. I started washing my hands straight away and it didn’t repeat. I wouldn’t call it instant relief, it’s more a steady control.
15 Jun 2025
Sources
- European Medicines Agency (EMA) (2026). Tiotropium: European public assessment and product information summary.
- World Health Organization (WHO) (2026). Chronic obstructive pulmonary disease (COPD): guidance and essential management principles.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2026). Global Strategy for the Diagnosis, Management, and Prevention of COPD.
- Global Initiative for Asthma (GINA) (2026). Global Strategy for Asthma Management and Prevention.
- MOHAP (Ministry of Health and Prevention) (2026). Medication safety guidance for inhaled respiratory therapies and anticholinergic agents.
